NCT00287079View on ClinicalTrials.gov

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Clinically Isolated Syndrome
Interventions
DRUG

Rebif®

44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks

OTHER

No Treatment

No treatment for 96 weeks

Trial Locations (1)

Unknown

Canadian Medical Information Office, Windsor, Barrie, Hamilton, Mississauga

All Listed Sponsors
collaborator

EMD Serono Canada Inc.

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00287079 - A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome | Biotech Hunter | Biotech Hunter